Phase I/II Study of Tolerance and Pharmacokinetics With Capecitabine Given 5 Days Out of 7 in Metastatic Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Capecitabine (Primary)
- Indications Advanced breast cancer; Breast cancer
- Focus Adverse reactions; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 11 Sep 2008 Interim results reported at the ASCO Breast Cancer Symposium 2008.
- 11 Sep 2008 Status changed from recruiting to active, no longer recruiting.